Syncytium forming capacity of HIV 1 strains in inhibited by pretreatment of CD4 expressing cells with 3'-azido-3'-deoxythymidine but not by alpha interferon.
3'azido-3'deoxythymidine (AZT) inhibits the ability of uninfected CD4 expressing cells to participate in syncytium formation, when cocultured with cells chronically infected with human immunodeficiency virus type 1 (HIV 1). The inhibition of giant cells formation is similar, irrespective of the AZT-sensitive or resistant phenotype of the HIV1 strains. The effect on syncytium formation occurs when the uninfected target cells are pretreated with AZT, the therapeutic index varying between 290 (CEMss, H9 and > 2000 (HeLa CD4 beta gal). The syncytium reducing effect of AZT is an additional antiviral property, distinct from the inhibition of HIV replication. The HIV 1 phenotype (AZT sensitive or resistant) determines differences both in the morphology of syncytia and in the kinetics of syncytium formation. Pretreatment of the target cells with alpha interferon (125-2000 UI/ml) either alone or in combination with AZT, has no effect on the ability of these cells to participate in syncytium formation, probably owing to the basal IFN synthesis in the system.
Ruţă
S M
SM
Stefan S. Nicolau Institute of Virology, Bucharest, Romania.
Cernescu
C
C
D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000473:pathology / Q000821:virology*; D002459:Cell Fusion; D015726:Giant Cells / Q000187:drug effects / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000472:pathogenicity; D006367:HeLa Cells; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology*; D007700:Kinetics; D010641:Phenotype; D012680:Sensitivity and Specificity; D015215:Zidovudine / Q000494:pharmacology*
D016898:Interferon-alpha; D015215:Zidovudine